Comparative Pharmacology
Head-to-head clinical analysis: DEXFERRUM versus FERRISELTZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXFERRUM versus FERRISELTZ.
DEXFERRUM vs FERRISELTZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iron replacement therapy; provides iron for hemoglobin synthesis and erythropoiesis in iron-deficiency states.
Ferric iron (Fe3+) from ferric citrate reduces phosphate absorption by forming insoluble ferric phosphate complexes in the gastrointestinal tract, reducing serum phosphate levels. Iron is absorbed and incorporated into hemoglobin.
100 mg intravenously over 2-5 minutes; may repeat if indicated (total dose depends on iron deficit).
325-650 mg orally once daily; ferrous sulfate 325 mg (equivalent to 65 mg elemental iron).
None Documented
None Documented
Terminal elimination half-life: 2.3–3.5 hours in adults with normal renal function. Closely follows iron kinetics; clinical effect persists beyond half-life due to intracellular iron utilization.
Not applicable for iron absorption; serum iron levels peak at 1-2 hours post-dose and decline with a half-life of approximately 6 hours, reflecting gastrointestinal absorption and distribution.
Primarily renal: ~60% as intact drug; ~20% as metabolites. Biliary/fecal: ~15% as metabolites. Unchanged drug in feces <5%.
Ferric citrate is primarily eliminated via feces as unabsorbed drug (approximately 70-80%). A small fraction is absorbed and excreted renally (less than 1% of ingested dose).
Category C
Category C
Iron Supplement
Iron Supplement